Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK Study of CT-P43 (Ustekinumab Biosimilar) in Healthy Males
NCT04428814Phase 1Completed
- Sponsor
- Celltrion
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ustekinumab CT-P43 in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (5 arms), sponsored by Celltrion. Primary endpoint: Demonstrate PK similarity at Day 127. Started Aug 2020; status: completed.
02
Drugs
ustekinumab CT-P43
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04428814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428814.